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Antonia M. S. M€uller,1 Holbrook E. K. Kohrt,2 Steven Cha,2 Ginna Laport,1 Jared Klein,3
Alice E. Guardino,2 Laura J. Johnston,1 Keith E. Stockerl-Goldstein,4 Elie Hanania,5
Christopher Juttner,6 Karl G. Blume,1 Robert S. Negrin,1
Irving L. Weissman,7 Judith A. Shizuru1,7Metastatic breast cancer remains a major treatment challenge. The use of high-dose chemotherapy (HDCT)
with rescue by autologous mobilized peripheral blood (MPB) is controversial, in part because of contamina-
tion of MPB by circulating tumor cells. CD341Thy-11 selected hematopoietic stem cells (HSC) represent
a graft source with a greater than 250,000-fold reduction in cancer cells. Here, we present the long-term
outcome of a pilot study to determine feasibility and engraftment using HDCTand purified HSC in patients
with metastatic breast cancer. Twenty-two patients who had been treated with standard chemotherapy were
enrolled into a phase I/II trial between December 1996 and February 1998, and underwent HDCT followed
by rescue with CD341Thy-11 HSC isolated from autologous MPB. More than 12 years after the end of the
study, 23% (5 of 22) of HSC recipients are alive, and 18% (4 of 22) are free of recurrence with normal he-
matopoietic function. Median progression-free survival (PFS) was 16 months, and median overall survival
(OS) was 60 months. Retrospective comparison with 74 patients transplanted between February 1995
and June 1999 with the identical HDCT regimen but rescue with unmanipulated MPB indicated that 9% of
patients are alive, and 7% are without disease. Median PFS was 10 months, and median OS was 28 months.
In conclusion, cancer-depleted HSC following HDCTresulted in better than expected 12- to 14-year PFS and
OS in a cohort of metastatic breast cancer patients. These data prompt us to look once again at purified HSC
transplantation in a protocol powered to test for efficacy in advanced-stage breast cancer patients.
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Autologous hematopoietic cell transplantation
(auto-HCT) is widely used to treat patients with hema-
tologic malignancies and selected solid tumors consid-
ered incurable by standard treatments [1]. The
rationale for auto-HCT is based on the concept that
cancer cell resistance can be overcome by dose escala-
tion of chemotherapy, as dose-response relationships
have been established for many cancers [2,3]. Because
a major dose-limiting toxicity of chemotherapeutic
agents is severe damage to hematopoiesis, patients
must be ‘‘rescued’’ with their own blood-forming cells.
Although treatment-related mortality after auto-HCT
is\5%, the risk of inadvertently reinfusing cancer cells
with the grafts, thereby contributing to subsequent
recurrence, remains an unresolved concern.
Primarymalignancies of thebloodandmanycancers
of nonhematopoietic origin reside in or circulate125
126 Biol Blood Marrow Transplant 18:125-133, 2012A. M. S. M€uller et al.through the bone marrow (BM). Standard histologic
methods are insufficient to detect occult tumor
cells [4-6]. Following treatment with induction
chemotherapy, micrometastases of BM have been
reported in 36% of stage I-III patients [7], and up to
52%, 57%, and 82% in patients with stage II, III, and
IV breast cancer, respectively, when molecular detec-
tion methods were applied [6]. Mobilized peripheral
blood (MPB) is the most common type of graft used
for rescue after high-dose chemotherapy (HDCT).
MPB is obtained before transplantation. Although
MPB is reportedly less frequently contaminated than
BM [5], there is evidence that the process of mobilizing
of stem cells out of themarrow recruits tumor cells into
the bloodstream [8]. Indeed, breast cancer cells have
been identified in autologous rescue products, includ-
ing CD341selected MPB grafts [9,10]. Sensitive
immunohistochemical assays capable of detecting 0.5
to 40 cells tumor cells in 106 cells have shown that
tumor contamination was measurable in 8% to 37%
of such products [10-14], and over 70% when PCR
was applied [15].
Althoughmultiple analyses have attested to the po-
tential importance of tumor cell contamination in the
infusion product on transplant outcomes [11,16,17],
the question of whether or not purging of tumor
cells is important remains unanswered. The strongest
argument against purging is the observation that
most patients who relapse after auto-HCT do so at
the sites of prior disease [18].
Recent evidence supporting the importance of tu-
mor cell eradication from autologous grafts comes
from studies in mice demonstrating that circulating or
infused breast, colon, or melanoma cancer cells can
home to tumor-bearing sites, such as mammary glands
infiltrated with mammary adenocarcinomas, but not
to unaffected glands [19]. These data corroborate with
older gene-marking studies that attempted to trace the
origin of relapse in humans [20,21], and showed that
tumor cells included in an HCT inoculum can
contribute to disease recurrence at a prior tumor site.
Thus, if tumor recurrence were to occur by seeding,
the permissive environments of prior disease sites are
likely places where disease would recur. These recent
observations prompted us to reexamine long-term out-
comes of a previously conducted trial using purified he-
matopoietic stem cells (HSC).
Given the concerns of cancer cell contamination in
auto-HCT, we conducted a phase I/II study between
December 1996 and February 1998, analyzing the safety
and feasibility of transplantation of highly purified HSC
in patientswithmetastatic (stage IV and recurrent) breast
cancer. A methodology to positively select HSC from
MPBbased on expression of CD34 andThy-1with fluo-
rescence activated cell sorting (FACS)was used to gener-
ate grafts in which breast cancer cells were not detected
by an assay that could identify 1 tumor cell in 106 cells.This study confirmed that the isolation of sufficient
numbers of extensively FACS purified CD341Thy-11
HSC was feasible, and that hematopoietic rescue from
the selected cells was fully preserved [10].
Our study was initiated in an era when multiple
phase II studies indicated that patients with metastatic
breast cancer can benefit from auto-HCT [22-24], and
thousands of women with this unfavorable disease
were treated by this approach. However, subsequent
randomized Phase III trials did not confirm the
superiority of HDCT over conventional dose
chemotherapy (CDCT) for treatment of advanced
breast cancer [25-29], and clinical trials of auto-
HCT for the treatment of breast cancer were halted
(supplemental text). One potential reason for the fail-
ure of auto-HCT trials to demonstrate improved out-
comes is the high rate of occult BM involvement in
breast cancer patients.
Here, we report the long-term results of metastatic
breast cancer patients who underwent transplantation
with highly purified HSC. Further, we retrospectively
assessed the outcomes of patients with metastatic
breast cancer, given the same conditioning regimen
but conventional MPB.PATIENTS AND METHODS
Patients and Eligibility
Womenwith primarymetastatic or recurrent breast
cancer were enrolled on a phase I/II trial to test purified
HSC at 2 centers: Stanford University Hospital (SUH,
Palo Alto, CA) and the Barbara Ann Karmanos Cancer
Institute (BAKCI, Detroit, MI). Enrollment was from
December 1996 to February 1998. Eligibility criteria
are listed in the supplements and have been reported
by Negrin et al. [10]. Enrollment was based on consec-
utive order and capacity to sort cells for the study.
Nine patients received unmanipulated MPB rather
than HSC grafts because of insufficient mobilization
to proceed to cell sorting and/or CD34-expression of
the cancer cells (n5 6). Seventy-four patients withmet-
astatic BC, who underwent auto-HCT with the identi-
cal HDCT regimen as in the HSC trial but who were
given unmanipulated MPB grafts at SUH between
February 1995 and June 1999, were also analyzed.
Data documentation and analysis were performed
according to the guidelines of the Declaration of
Helsinki and good clinical practice. All patients signed
informed consent approved by the institutional review
boards of the respective centers. For this analysis, living
patients were censored as of July 31, 2010.
Stem Cell Isolation, Cryopreservation, High-
Dose Chemotherapy, and Stem Cell Infusion
HSC were isolated from CD341-column enriched
hematopoietic apheresis products by FACS, according
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ceeding 90% in all cases (median of 95.3%). Details of
the mobilization of the hematopoietic stem/progeni-
tor cells, enrichment, cryopreservation, conditioning
regimen, and statistics applied are provided in the sup-
plements.
Assessment of Graft Tumor Contamination
To detect and quantify breast cancer cell contam-
ination of apheresis products and purified populations,
cells were stained with anti-CD34 antibody (9C5), fol-
lowed by a secondary antibody (goat antimouse
Ig-Texas Red), and fixed on cytospins. Slides were
then stained with a cytokeratin cocktail (CAM
5.2-FITC and KL1-FITC) and analyzed using a Zeiss
Axioplan fluorescent microscope (Carl Zeiss, Thorn-
wood, NY) with Texas Red/FITC filters.RESULTS
Patient Characteristics
Twenty-two women were enrolled in a phase I/II
study of auto-HCT and rescue with CD341Thy-11
HSC (HSC trial). Table 1 shows detailed characteris-
tics and survival information for individual patients in
this trial. Figure 1 shows that the methodology used
for CD341901 HSC selection from MPB by high-
speed FACS sorting depletes MPB deliberately con-
taminated with breast cancer by 245,000 fold.
Table 2 summarizes prognostic information for
patients in the HSC trial cohort and the 74 womenTable 1. Patient Characteristics of HSC Trial (CD34+Thy1+ HSC)
Patient Age
U
R
Metastatic
Sites ER PR
No. of CDCT
(Regimen/Cycl
S1 40 R B, BM + + 2 [6,4]
S2 41 R B, Lo, N 2 + 2 [6,2]
S3 41 U IBC, SCN 2 2 1 [4]
S4 50 R SCN 2 2 2 [4,1]
S5 49 R Lo 2 + 3 [6,4,3]
S6 36 U S, CW 2 2 2 [3,4]
S7 42 R N 2 2 2 [4,2]
S8 47 U B 2 2 1 [4]
S9 43 R SCN 2 2 3 [6,4,2]
S10 44 U SCN + 2 1 [4]
S11 37 R SCN + 2 4 [4,4,4,4]
S12 46 R P + + 3 [6,4,2]
S13 51 U B + + 2 [3,6]
S14 46 R B, S, N 2 2 4 [6,4,2,1]
S15 34 R B + + 3 [4,4,7]
D1 41 B + + 2 [6,2]
D2 50 B, BM 2 2 1 [4]
D3 46 NA NA NA NA
D4 47 B, BM + + 1 [4]
D5 59 B, BM + 2 1 [3]
D6 51 B, BM + 2 1
D7 32 B, BM 2 2 2 [6,2]
U indicates upfront (newly diagnosed stage IV); R, relapse. Metastatic site: B,
breast cancer; SCN, supraclavicular lymph node; S, skin; CW, chest wall; E
HCT, hematopoietic cell transplantation; OTC, occult tumor cells. Current stat
D-REL, death because of relapse; PFS, progression-free survival; OS, overall swho received the identical HDCT conditioning regimen
but were rescued with unmanipulated MPB. Median
age, histology, steroid receptor status, timing of trans-
plantation (‘‘upfront’’ as consolidation after CDCT for
newly diagnosed breast cancer vs HDCT for recurrent
disease), status of remission before transplantation, and
metastatic sites are listed for both cohorts.
Patients with a complete response (CR), partial re-
sponse (PR), or with stable disease (SD) were permit-
ted to enter the study. Nine of 22 patients in the
HSC trial had more than 1 site of metastases. The
most common sites of metastases were bones (52%),
followed by lymph nodes (33%), and BM (29%). In
24% of patients, soft tissues were primarily affected
(local relapse, skin, or chest wall), without bone or vis-
ceral involvement, including 1 patient with inflamma-
tory breast cancer (IBC). One patient had visceral
metastasis (lung). One patient with breast cancer diag-
nosed in a supraclavicular lymph node was considered
as havingmetastatic disease according to the old TNM
classification before the 2002 revision [30], and re-
ceived auto-HCT within the upfront treatment. In
theMPB cohort, 31% of patients had visceral metasta-
sis, and 32% had bone disease without visceral metas-
tasis. Thirteen patients had local recurrence within the
soft tissue or the chest wall with or without lymph node
involvement, and 14 patients had recurrence limited to
the lymph nodes.
Tumor Cell Depletion
Six of the 22 patients who underwent transplanta-
tion in the HSC trial had evidence of cytokeratin-es)
Remission
at HCT OTC
Current
Status
PFS
(Months)
OS
(Months)
PR (BS) A-CR 163.9 163.9
CR + A-CR 160.9 160.9
CR + A-CR 159.5 159.5
CR + A-CR 157 157
CR A-REL 7.7 150
CR + D-REL 12.2 41
CR D-REL 16.8 24
PR (BS) D-REL 12 59.8
PR D-REL — 4.4
CR D-REL 50.2 146.4
PR D-REL 15.3 123.4
SD D-REL 28.3 53.6
SD (BS) D-REL 49.1 102
SD D-REL 6.3 120
SD D-REL 55.3 60
SD + D-REL 13.8 13.8
SD + D-REL 21.8 36
NA D-REL 6 7.8
SD D-REL 6
SD D-REL 4.5 6
SD D-REL 6.5 6.5
SD D-REL 16.4 29
bone; BM, bone marrow; Lo, local; N, lymph nodes; IBC, inflammatory
R, estrogen receptor; PR, progesterone receptor; NA, not available;
us: A-CR, alive in complete response; A-REL, alive with relapsed disease;
urvival.
CD34+ magnetic beads #1
CD34+ magnetic beads #2
0 100000 200000 300000
CD34+Thy-1+ FACS-sorted
CD34+ FACS-sorted
Figure 1. Comparison of fold depletion of cancer cells from MPB
using CD34 with and without Thy-1 as positive selecting markers for
high-speed cell sorting (FACS) as compared with CD34 magnetic bead
selection alone. MPB products were purposefully contaminated with
tumor cells, and the selected products were analyzed by an immuno-
flouresence (IFM) assay for breast cancer.
128 Biol Blood Marrow Transplant 18:125-133, 2012A. M. S. M€uller et al.positive cells in their apheresis products and/or after
CD341 cell selection with the Isolex (Baxter, Irvine,
CA) immunomagnetic positive selection device. No
tumor cells were detectable after CD341Thy-11
stem cell sorting in all patients tested. However, in 1
patient, insufficient cell numbers were available to re-
peat the immunofluoresence assay after HSC sorting.
This latter patient had cytokeratin-positive cells in
all 3 apheresis products.
Survival and Follow-up
SUH/BAKCI phase I/II trial (‘‘HSC trial’’)
More than 12 years after the end of the study, and
after a median follow-up of 60 months, 5 (23%) of the
22 patients given purified HSC are alive, and 4 (18%)
of them have no clinical evidence of disease.Table 2. Summary of Patient Characteristics
HSC Trial MPB
Patients (n) 22 74
Age (range) 45 (32-59) 46 (21-62)
Indication n 5 15
Upfront (%) 5 (33) 19 (26)
Relapse (%) 10 (67) 55 (74)
Hormone receptors (%) n 5 21 n 5 59
ER+/PR2 or ER+/PR ng 4 (19) 6 (10)/5 (8)
PR+/ER2 2 (9.5)
ER+/PR+ 6 (28.5) 27 (46)
ER2PR2 9 (43) 20 (34)
Metastatic sites (%) n 5 21 n 5 74
Bone 12 (57) 33 (45)
BM 6 (28.5) 1
Visceral 1 (5) 23 (31)
LN 3 (14) 10 (13.5)
SCN 4 (19) 15 (20)
S/Lo/CW 4 (19) 19 (26)
Remission at HCT (%) n 5 21
CR 6 (29) 26 (35)
PR 5 (24) 38 (52)
SD 10 (48) 7 (9)
PD 0 (0) 3 (4)
ER indicates estrogen receptor; PR, progesterone receptor; Metastatic
sites: BM, bone marrow; LN, lymph nodes; SCN, supraclavicular lymph
nodes; S, skin; Lo, local; CW, chest wall; Remission at HCT (hematopoi-
etic cell transplantation): CR, complete response; PR, partial response;
SD, stable disease; PD, progressive disease.As described in our original publication in 2000,
recovery of neutrophils and platelets was prompt
[10]. Lymphocyte blood levels, which are dominated
by T cells, remained low to normal throughout the
first year. In the immediate posttransplantation set-
ting, B cells were completely absent in the blood but
recovered to normal levels by 6 months. Despite low
B cell numbers, serum immunoglobulin G (IgG) levels
were normal during the initial 6 months and thereafter
(Supplemental Figure 1).
The outcomes of the patients were as follows: 1 pa-
tient died of pneumonia with sepsis and multiorgan
failure 133 days post-HCT, whereas 16 patients died
because of tumor progression. Figure 2A and 2B show
(in gray) the Kaplan-Meier curves of progression-free
survival (PFS) and overall survival (OS). Median PFS
was 15.8months from the day ofHSC infusion.Median
OSwas 60months for the entire group, 47.3months for
those who relapsed, and 160 months for the survivors.
The 3-, 5-, and 10-year OS rates were 64%, 45%, and
32%, respectively.
Although all patientsmet the inclusion criteria of the
phase I/II HSC trial, the 15 patients enrolled at SUH
fared better compared with the 7 patients treated at the
BAKCI. Long-term evaluation at 10 years revealed thatFigure 2. Progression-free survival (PFS) (A) and overall survival (OS)
(B) in patients undergoing HCTwith purified HSC (n5 22; gray) versus
unmanipulated mobilized peripheral blood (black).
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evidence of breast cancer, whereas all BAKCI patients
relapsed within 2 years. This discrepancy is attributed
to differences in patient selection between the 2 institu-
tions. SupplementalTable 1 provides the patient charac-
teristics separated into the 2 transplant institutions, and
supplementalFigure2Aand1Bdisplay theKaplanMeier
curves of PFS andOS for both groups. The main differ-
ence between these subgroups appears to be that the
SUH cohort included mainly chemosensitive patients,
of which 7 of 15 had achieved had a CR, 4 of 15 a PR,
and only 3 of 15 had SD at the time of HCT, whereas
none of the patients in the BAKCI group had a demon-
stratedCRor PR to prior treatment at the time ofHCT.
SUH retrospective cohort
The STAMP1 regimen [31] was the standard
HDCT regimen used for treatment of patients with
breast cancer at SUH after 1994. Seventy-four women
with metastatic breast cancer received auto-HCT
and rescue with MPB between February 1995 and
June 1999. Of the entire group, 7 patients (9%) are
alive, and 5 (7%) are without disease. Sixty-seven
patients died, and the majority of deaths were because
of tumor progression (n5 55, 74%); 12 women (16%)Figure 3. OS of 22 recipients of purified HSC (gray) as compared to the coho
positive and ER-negative breast cancer; (B) relapsed breast cancer or patients w
their upfront treatment; (C) visceral metastasis versus bone, but no visceral m
(D) complete response (CR), partial response (PR), or stable or progressive ddied without evidence of recurrence, 9 of them before
day 200 post-HCT. Three patients (4%) were lost to
follow-up. Figure 2A and 2B show (in black) the
Kaplan-Meier curves of the PFS and OS. Median PFS
was 10 months from the day of MPB infusion. Median
OSwas 28months for the entire group, and 154months
for the 7 survivors. The 3-, 5-, and 10-yearOS rateswere
39%, 28%, and 13.5%, respectively.
Subgroup analysis
To examine parameters that might aid in identifi-
cation of patients who would be best served by an
auto-HCT, we evaluated different subgroups of the
MPB cohort. We also performed this analysis to
identify which parameters might have contributed to
a selection bias in the HSC trial.
In our retrospective data set of patients given
unmanipulated MPB, the hormone receptor status
was assessed in 59 of 74 patients. Comparisons of the
OS of patients with tumors expressing estrogen recep-
tor (ER) versus those with ER-negative disease showed
no differences (Figure 3A). A higher proportion of
patients in the HSC trial had ER-negative disease
(53% vs 34%), a known poor prognostic indicator.
Nonetheless, the HSC patients had superior OS.rt given MPB, subdivided into patients with (A) estrogen receptor (ER)-
ith newly diagnosed metastatic disease undergoing auto-HCTas part of
etastasis versus local recurrence versus exclusively lymph node disease;
isease (SD/PD).
130 Biol Blood Marrow Transplant 18:125-133, 2012A. M. S. M€uller et al.In the MPB group, patients with newly diagnosed
metastatic breast cancer who had undergone upfront
auto-HCT (after induction CDCT) had better OS
compared with women receiving HDCT for recurrent
disease (P 5 .057).
Regarding the metastatic sites present in women
receiving intensified treatment, visceral metastases
(with/without other metastatic sites) were associated
with the worst outcome, followed by bone involve-
ment (but no visceral metastases). Patients with local
recurrence, or exclusively lymph node metastases,
appeared to have better OS.
The majority of patients given HDCT with con-
ventional MPB were responsive to CDCT, with
a CR rate of 35% and a PR rate of 51%, accounting
for an overall response rate of 86%. The pretransplan-
tation response rates of patients in the HSC trial were
lower, with 29% and 24% of trial patients in CR and
PR, respectively, for an overall response rate of 53%.
MPB recipients with SD or PD at the time of
HDCT had inferior OS compared with patients who
achieved a PR or CR.
None of the differences in outcomes for the
subgroups reached statistical significance.DISCUSSION
We report here the long-term outcomes of a phase
I/II study, which treated women with metastatic breast
cancer with HDCT and rescue with purified HSC
grafts. A primary goal was to evaluate the ability of
such highly purified HSC to provide immediate and
sustained hematopoiesis. The long-term posttrans-
plantation course of survivors was remarkable for nor-
mal hematopoiesis and no secondary malignancies.
These data are the longest follow-up for recipients of
highly selected HSC. Three other studies similarly
used FACS purified HSC to treat multiple myeloma
and lymphoma. However, long-term data from these
studies have not been reported [32-34].
The secondary objective of our study was to evalu-
ate the effect ofHDCT and rescue with grafts depleted
of tumor cells onbreast cancer outcomes.At a detection
level of 1 cancer cell per 106 cells, there were no meas-
ureable tumor cells in the grafts. The high rate of sur-
vivors in this cohort of patients with a very unfavorable
prognosiswas unexpected. As is the case formany of the
reported phase I/II trials of auto-HCT in metastatic
breast cancer, ours was a small study, and we assume
that patient selection bias contributed to the positive
outcomes observed. However, the immense need for
curative treatment strategies in advanced breast cancer
prompted us to thoroughly evaluate the data set of the
HSC recipients and compare them with similar
patients at our center, who were given the identical
HDCT regimen but who were rescued with unmanip-ulated MPB. Results for recipients of MPB were con-
sistent with those of published phase III trials for
metastatic breast cancer (Table 3) [25-29,35-38].
Except for the low proportion of patients with
visceral metastases in the HSC group, no other
obvious prejudicing characteristic(s) were noted
between recipients of HSC versus MPB. In fact, the
status of remission before HCT was more favorable
in the group treated with standard MPB grafts
compared with the HSC group. Within the actual
HSC recipient group, marked differences in outcome
were observed between the 2 participating centers.
The basis for these differences is, as suggested by
a review of the patient characteristics, the inferior
remission status of the BAKCI as compared with
SUH patients at the time of auto-HCT.
Our HSC study was conducted in the late 1990s be-
fore the time when larger phase III trials of HDCTwith
MPB rescue showed prolonged PFS but failed to show
improved OS in patients with metastatic breast cancer.
Controversy and rejection of HDCT and auto-HCT as
treatments for advanced-stage breast cancer followed
these results to the degree that no new studies have
been reported that use the auto-HCTapproach to exam-
ine rationale and scientificquestions.As shown inTable3
and discussed byNieto and Shpall [39] and in the supple-
mental online materials, many of the phase III studies
were underpowered to detect realistic differences. Fur-
ther, the trials used different drug combinations, and
theobjectivesof the trialsweremarkedlydifferent, testing
HDCT versus standard treatment, HDCT for consoli-
dation of a CR versus salvage after relapse [25-29,38],
or single versus tandem HDCT [37] in pretreated and
in previously untreated patients [29,38]. Regardless, a
uniform feature of these trials was the use of unmani-
pulated MPB as the rescue graft.
The frequent recurrence of breast cancer predomi-
nantly at previous tumor sites was taken as evidence
that the chemotherapy protocols were insufficient to
eliminate local cancer. Challenging this assumption
are the gene marking studies from that era, which
showed that infused tumor cells are present at the site
of disease relapse [20,21], as well as clinical studies that
demonstrated worse outcomes for auto-HCT patients
who received grafts with detectable breast tumor cells
[6,16]. Moreover, the recent reports by Norton and
Massague [19,40] demonstrating that circulating
breast cancer cells preferentially reseed former tumor
sites provide a further explanation why injected cancer
cells, present as contaminants in MPB, might facilitate
tumor recurrence in sites of prior disease. Taken
together, the studies suggest that tumor contamination
is deleterious and that better results can be achieved by
eliminating cancer cells from the graft.
Currently, metastatic breast cancer has a poor
prognosis, with a 10-year survival of less than 5% and
an overall median survival of approximately 24 months
Table 3. Phase III Trials on HDCT in Metastatic Breast Cancer (MBC)
Group Inclusion Patients (n) HDCT Metastases Median FU (m) Median PFS (m) Median OS (m) PFS Rate OS Rate
HDCT versus CDCT
Philadelphia Intergroup
(ECOG)*
>PR to IDCT R 5 199 CTCb 37 3 years: 3 years:
H 5 110 [T 5 89] V58% 9.6 24 6% 32%
C 5 89 [T569] V43% 9.0 (P 5 0.31) 26 (P 5 .14) 12% 38%
Pegase 03 >PR to IDCT R 5 179 CT 48 3 years: 3 years:
H 5 88 [T 5 79] L57%, P30%, B51% 11 23 8.8% 33.6%
C 5 91 L50%, P34%, B49% 6.6 (P 5 .0001) 24 2.1% (P 5 .0001) 24.3% (P5.8)
Pegase 04 Responders to A R 5 61 CMA 2/5 years: 2/5 years:
H 5 32 [T 5 28] L28%, P47%, B38% 92 12 44.1 37.5/18.7% 65.6/36.8%
C 5 28 L38%, P21%, B55% 87 6 (P < .0056) 19.3 (P < .0294) 13.8/0% 37.9/13.8%
NCIC-M-16* Responders to IDCT
or untreated
R 5 224 CMCb V42%, B58% 48 3 years:
H 5 112 [T 5 91] L27%, P13%, B59% 11 24 37%
C 5 112 L28%, P21% 9 (P 5 .006) 28 (P 5 .43) 38%
IBDIS-1*† Untreated MBC R 5 110 55 42 months: 42 months:
H 5 56 Cb/CT ng ng ng 25% 39%
C 5 54 20% 35%
Schmid* Untreated MBC R 5 93 CME V87% (L 5 70%,
P42%, B48%)
52 2/3 years: 3/4 years:
H 5 48 [T41/39] 11.1 26.9 26.7/8.9% 20.8/8.3%
C 5 45 10.6 (P 5 .6) 23.4 (P 5 .6) 20.9/9.3% 18.2/13.6% (P 5 .41)
Immediate HDCT versus salvage HDCT
Duke Crossover >PR to IDCT R 5 100 CPB V69%, L35% 127 10.3 21 5 years: 15% 5 years: 20%
Hcons 5 49 9.7 25.3 26%
Hsalv 5 51 3.8 (P < .006) 38.4 (P 5 .2) 10%
Duke Crossover Bone disease only R 5 69 CPB B100% 97 Publication:
Hcons 5 35 12 2.97 17%
Hobs 5 34 4.3
Hsalv 5 27 5 (P 5 .0051) 1.81 9%
Single versus tandem HDCT
Kroeger R 5 187 CTCb 62 for survivors 10.3 24.8 2/5 years: 5 years:
H1# 5 94 [T 5 86] V62%, Bonly 13% 9.4 29 10/6% 20%
H2# 5 93 [T 5 85/52] V61%, Bonly 10% 11.2 (P 5 .06) 23.5 (P 5 .4) 19.6/8% 20%
IDCT indicates induction chemotherapy; R, randomized; H, HDCT arm; [T], actually treated with HDCT; C, CDCT arm; HDCT regimen: C, cyclophosphamide; T, thiotepa; Cb, carboplatin; M, mitoxantrone;
A, melphalan; E, etoposide; P, cisplatin; B, BCNU; Metastases: V, visceral; L, liver; P, pulmonary; B, bone; FU, follow-up; PFS, progression-free survival; OS, overall survival; PR, partial remission.
*Terminated prematurely.
†Abstract only.
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132 Biol Blood Marrow Transplant 18:125-133, 2012A. M. S. M€uller et al.[41,42]. Although some subsets of patients have a higher
incidence of long-term survival, such as those who ex-
press estrogen receptors and are treated with hormonal
therapies, palliative therapieswith preferablyminimally
toxic agents are the mainstay of treatments. For over
a decade, the intensified therapy approach has remained
dormant for this disease, despite pertinent advances
made in the field of HDCT and auto-HCT for other
malignancies. In our small study, provision of purified
HSC in the rescue transplantation resulted in better
than expected 12- to 14-year OS and PFS in a cohort
of metastatic breast cancer patients. Considering the
limitations of current treatments and the many ques-
tions that still remain as to howbest to treat this disease,
our long-term data have encouraged us to look once
again at auto-HCT for patients with metastatic breast
cancer. Now that we have demonstrated the long-
term safety of this approach, a comparative study of
properly characterized subjects treated with high-dose
therapy using cancer-freeHSCgrafts versus the current
standard of care is appropriate. The intensive therapy
approach could further serve as a platform for subse-
quent maintenance with novel biologic (antibody or
small molecule agents) within amultimodal rescue pro-
tocol for advanced-stage breast cancer patients, and
perhaps for other malignancies.ACKNOWLEDGMENTS
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